Prachee Bhartiya oprettet en ny artikel
52 i

Exploring Opportunities and Trends in the Antibody Therapeutics Market | #antibody Therapeutics Market

Exploring Opportunities and Trends in the Antibody Therapeutics Market

F. Hoffmann-La Roche Ltd. entered into a definitive agreement to acquire Televant. Through this agreement, Roche received the development, manufacturing and commercialization rights in the US and Japan for Telavant’s RVT-3101, a novel TL1A directed antibody.